Clinical Trial

Safety and Efficacy of Meplazumab in Patients With Coronary Artery Disease

Study acronym: REC-SAFECAD
Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
The development of coronary atherosclerosis is closely related to inflammation, and CD147 may play an important role in its process. The present study was designed to evaluate the effects of long-term administration of mepolizumab (humanized anti-CD147 antibody) on lipid deposition and inflammation in coronary atherosclerotic plaques in patients with high-risk coronary artery disease, and to preliminarily explore the efficacy, safety, and dosage of long-term administration of mepolizumab in this population.
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2024-08-24; most recent amendment 2026-01-22.
Trial Details
NCT Number NCT06572267
Lead Sponsor Xijing Hospital
Conditions Coronary Artery Disease
Enrollment 18 participants
Start Date 2024-10-16
Primary Completion 2026-09-01 (estimated)
Study Completion 2027-03-01 (estimated)
Updated on ClinicalTrials.gov 2026-01-23